Deutsche Bank’s Take On Big Pharma: 3 Buys And A Hold
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) IBB up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for three of the biggest biotech names in the market.